Usefulness of compounds with monacolin K in a case of statins intolerance

  1. Parra-Virto, Alejandro
  2. Torres do Rego, Ana
  3. Demelo-Rodríguez, Pablo
  4. Millán Núñez-Cortés, Jesús
  5. Álvarez-Sala, Luis A.
Journal:
Clínica e investigación en arteriosclerosis

ISSN: 0214-9168 1578-1879

Year of publication: 2018

Volume: 30

Issue: 6

Pages: 268-270

Type: Article

DOI: 10.1016/J.ARTERI.2018.06.003 DIALNET GOOGLE SCHOLAR

More publications in: Clínica e investigación en arteriosclerosis

Sustainable development goals

info

SDG classification obtained using Aurora SDG artificial intelligence model.

Abstract

Many patients with familial hypercholesterolaemia (FH) or in secondary prevention situations and with statin intolerance do not achieve LDL-C targets, and require treatment with PCSK9 inhibitors (iPCSK9) and ezetimibe. The case is presented on a patient with FH and total intolerance to statins. Treatment with iPCSK9 and ezetimibe failed to achieve her LDL-C target. A compound with red yeast rice derivatives containing 3 mg of monacolin K was added, with good therapeutic compliance, and a very good control of LDL-C. The addition of red yeast rice derivatives containing low doses of monacolin K, together with IPCSK9 in patients with total intolerance to statins, may open a new path to obtain LDL-C targets in patients with high/very high cardiovascular risk.